Financials data is unavailable for this security.
View more
Year on year Aytu Biopharma Inc grew revenues 11.10% from 96.67m to 107.40m while net income improved from a loss of 108.78m to a smaller loss of 17.05m.
Gross margin | 65.32% |
---|---|
Net profit margin | -14.60% |
Operating margin | -1.53% |
Return on assets | -9.91% |
---|---|
Return on equity | -38.18% |
Return on investment | -25.58% |
More ▼
Cash flow in USDView more
In 2023, Aytu Biopharma Inc increased its cash reserves by 18.72%, or 3.63m. Cash Flow from Financing totalled 8.87m or 8.26% of revenues. In addition the company used 5.13m for operations while cash used for investing totalled 117.00k.
Cash flow per share | -1.02 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 5.53 |
---|---|
Tangible book value per share | -4.19 |
More ▼
Balance sheet in USDView more
Current ratio | 0.8499 |
---|---|
Quick ratio | 0.6923 |
Total debt/total equity | 0.5431 |
---|---|
Total debt/total capital | 0.352 |
More ▼